In humans the HIV infection results in a chronic
Introduction
The disease caused by the human immunodeficiency virus (HIV) can be best characterized by the progressive tall of CD4+ T-cell count and by the disruption of the lymphoid tissue architecture leading to severe immunodeficiency and death of the infected patient. There is a permanent tight during this process between factors controlling HIV and evolution of HIV-quasispecies escaping the control. The AIDS-research of recent years has mostly focused on understanding how neutralizing antibodies and CTL lymphocytes work and what their role is in the control of HIV disease. There are, however, some other factors namely, complement proteins and some types of antibodies, which are less known in the control of HIV disease. In this review we would like to summarize the research carried out in the past years in this field, including the work of thes group of authors.
Traditionally, the reason for lack of disease caused by retroviruses in human beings was thought to be a consequence of the lytic action of human complement on RNA tumor viruses. 48 The receptor for the Clq subcomponent the first componenl (C1) of the classical pathway was shown to be a small fragment (pl5E) of the transmembrane glycoprotein in the case of the Moloney leukemia virus (MoLV). 2 This specific interaction leads to the activation of the classical complement pathway and subsequent lysis of the targeted virions. It was surprising when HIV was discovered, that the virus was not found to be lysed by human serum although it activated complement ~'9 by both its envelope glycoproteins.
The transmembrane glycoprotein gp41 of HIV activates the classical complement pathway
Like animal RNA tumor viruses, HIV itself activates the complement cascade via the classical pathway by specific binding of the Clq subcomponent to its transmembrane glycoprotein gp41. Figure 1 ). There is a high degree of sequence similarity between the C lq binding domain of gp41 and pl5E of MoLV. 4 Purified HIV virions bind Clq and activate the classical pathway 36 too, but this activation does not cause the lysis of the virions. One possible explanation for this phenomenon might be the presence of membrane-bound (decay accelerating factor, DAF, CD55 and CD59) and virion-associated (factor H) complement regulatory proteins (reviewed by Stoiber et aPS), acquired during and after the budding process. 9 In the infected patients ~~ the continuous complement activation resulted in a significantly elevated level of protein-protein complexes (mostly C 1 r-C I s-C 1 inh and C3b-Bb-P) indicating the operation of both classical and alternative complement pathways.
Since HIV in the body of infected patients interacts with complement in the presence of specific anti-HIV antibodies, our group started to study what is the influence of anti-HIV antibodies on the complement activation by HIV, and inversely, how complement activation affects antibody binding. It was demonstrated in our earlier work 6 that recombinant gp41 protein loses its ability to bind to specific anti-gp41 antibodies after preincubation in normal human serum. The effect was clearly due to complement activation. In the next few experiments the inhibition of antibody binding to gp41 was shown to be mediated by the Clq moleculeJ 7 Using synthetic peptides we were able to demonstrate that after preincubation with normal human serum and subsequent fixation of Clq, C4b and C3b fragments the binding of antibodies against the immunodominant domain was abolished, too. The fixation of these complement proteins is significantly increased in the presence of specific ,'mti-gp41 antibodies 17 and enhancing type Much less attention has been paid to the complement activating ability of the outer envelope glycoprotein gp 120 of HIV. There is a discrepancy in the literature about the complement activating ability of gpl20. Ebenbichler et al. 5 were not able to show complement activation or Clq binding to recombinant gpl20 preparation using normal human serum diluted 1:40, whereas Sfisal et al. 4t demonstrated classical pathway activation by glycosylated gp 120 molecules. The difference might lie in the varying glycosylation patterns of the preparations and in the different dilution of normal human serum used as complement source, since Haurum et al. 16 were able to show strong complement activation by glycosylated gpl20 proteins, too ( Table 1 ). The exact mechanism in this case seems to depend on the fixation of mannan-binding lectin (MBL) to high-mannose structures present on certain recombinant proteins and the subsequent trigger of the lectin-pathway of complement activation which leads to the deposition of C3b lYagments to gpl20. Our results (Table 2 ) seem to support this mechanism. We have measured the compleVol 3, No 4, 1997 298 PROHASZKA et al ment activating properties of different gp 120 preparations in parallel, and found very strong C3b fixation in case of glycosylated gpl20 incubated with serum containing MBL, whereas the same gpl20 molecule was not able to activate complement in MBL-depleted serum. In case of MBL-depleted but Clq-containing serum there was also a slight Ca++-dependent and independent C3b fixation, too, indicating that beside the lectin-pathway, gpl20 has an inherent ability to trigger both the classical and alternative pathways ( Table 2 and ref. 28 ). The gpl20 preparation expressed in CHO cells activated the classical pathway without fixation of MBL. This preparation was found previously to bind Clq and activate CP. 2s Different from gp41, antibodies reacting with gpl20 were not able to increase the amount of C3b fixed by the protein, and deposited C3b components did not abolish the binding of polyclonal anti-HIV antibodies, whereas the binding of a monoclonal enhancing antibody (694-D) was blockedf 8 Most probably this might be explained by the fact that the monoclonal reacted with a linear epitope (HIVenv 306-327, V3-1oop) demonstrated in the same study to fix significant amounts of C3b.
The complement activation triggered by the outer envelope glycoprotein might play a significant role in the adsorption of the virus to complement receptor carrying cells.
MBL-levels and progression of HI V-disease
Mannan-binding lectin, MBL (previously termed as mannan-binding protein, MBP) is a collectin belonging to the C-type lectin family] 8'47 MBL is a part of the complement system, 42 recognizing high mannose structures and triggering the so-called lectin-pathway of complement activation.
MBL-levels in HIV-1 infection
Mannan-binding lectin is claimed to play role in the host defence by mediating the killing of microorganisms. 47 Several studies 8'2635'14'31 aimed to determine the role of MBL in HIV-1 infection, but the results are controversial. Ezekowitz et al. s observed a tendency of elevated MBLlevels in ARC and AIDS patients compared to asymptomatic HIV-infected individuals. Previously, Nielsen et all 6 found the percentage (10%) of HIV-seropositive persons with an MBL-level undetectable by an EL1SA method to be significantly higher as compared to healthy persons (2.4%, p=0.027). Recently, Garred et al. ~4 found the homozygozity for variant MBL alleles (which results in very low MBL-levels) to be significantly increased in HIV-seropositive patients compared to controls (8.3% vs. 0.8%, p=0.005). In contrast to these findings, Senaldi et al 3s using another ELISA technique detected low MBL- 
MBL-levels and survival after HIV-I injection
There are disagreements concerning the effect of MBLlevels on the progression of the HIV disease in already infected individuals. According to the studies of Nielsen et a126 no association could be found between the MBL-levels and the CD4+ cell decline, the length of time between seroconversion and development of AIDS, or the duration of AIDS before death occurred. In contrast, Garred et al. ~4 reported on the influence of MBL-levels on the progression of HIV disease. Thcy lound the median survival time after the development of AIDS to be significantly (p=0.007) shorter among carriers of the variant alleles (both homozygous and heterozygous, causing a decreased serum level of MBL) compared to patients homozygous for the normal MBL alleles. According to our unpublished studies the serum concentration of MBL does influence survival in HIV-1 infection, however, in opposite direction as reported by Garred et al. TM We found an approximately four times higher hazard ratio for patients with high serum level of MBL to die alter the development of AIDS as compared to patients with low MBL-levels. This data, together with our previous study on the complement activating ability of MBL (Table 2 ) and the inverse correlation between MBL-levels and CD4+ cell count 3~ support our assumption that MBL may affect the progression of HIV disease in two ways: i, it can bind to gpl20 in the envelope of HIV virions resulting in the activation of the lectin pathway. Fragments of activated complement proteins may bind to the virions and increase their infectivity, ii, activation of the lectin pathway can be triggered by free gpl20 adsorbed to the CD4+ lymphocytes which may facilitate the destruction of these cells, and consequently the progression of HIV disease.
Complement dependent enhancing type antibodies in HIV-I infection
Antibody-dependent enhancement (ADE) of HIV-I infection means facilitation of viral replication and increased virus production in the presence of enhancing type antibodies. Two types of ADE exist (for more details see ref. 13): complement-mediated (C-ADE) and complement-independent (depending on the presence of antibodies and Fc-receptors). In the following sub-headings the phenomenon of complement-mediated antibody-dependent HIV-infection enhancement (C-ADE) will be discussed, since in the past years most research by our group was carried out in this field.
Mechanism of complement-mediated antibody-dependent enhancement of HIV-1 infection
At present, the exact mechanism of in vitro C-ADE is not completely understood. There are three major hypotheses (according to ref. 22) aiming to answer the question: why is the in vitro production of HIV in the presence of intact complement and certain antibodies more rapid than without these factors? (Table 3 ) These hypotheses can be summarized as follows, i. increased adhesion of HIV-antibody-complement complexes to FcR and/or CR carrying cells, ii. facilitation of HIV-target cell fusion by complement fragments deposited on HIV-virions, and iii. complement-activation products may have non-specific stimulatory effects on target cells resulting in enhanced virus production. June et al. 2~ were the first to report that C-ADE is mediated by an increased virus binding to MT-2 target cells. This data together with our recent study 3~ in which a further adhesion bridge (purified Clq connecting HIV to collectin receptors present on the target cells) was supposed, seem to support the first ,,increased adhesion" mechanism of C-ADE as the most important. 
Changes in the levels of complement dependent enhancing type antibodies
The phenomenon of C-ADE was first described under in vitro circumstances, but enhancing antibodies seem to occur (both in infected patients 33 and in animal models34'23), and play a role in vivo, 4~' too (see below).
According to our studies 12"44 the amount of complement-dependent enhancing antibodies gradually increases during a time period of several years in which most of our patients in the study developed AIDS-related clinical symptoms.
Clinical significance
Our group was the first to describe the clinical relevance of the complement-dependent enhancing type antibodies. 46'J2 According to our longitudinal and cross-sectional studies, the loss of neutralizing activity parallel with the increase of C-ADE correlates with the decline of CD4+ cell number and development of AIDS-related clinical events. There are other studies performed by Montefiori et al with controversial results on the clinical relevance of the complement-dependent enhancing antibodies, 24' 25 but as we discussed it in detail 44' 13 the discrepancy between the results of Monteliori et al and our group might lie in methodological differences resulting in different sensitivity of the assay.
Autoantibodies in HIV-1 infection
This section summarizes our results on certain autoantibodies present in the sera of HIV-1 infected patients. These autoantibodies were studied in the same cohort of 
Autoantibodies mimicking MHC molecules
In cooperation with Stisal et al we reported on lgGand IgA-type autoantibodies reacting with the Fab part of the human IgG molecule, 4~ correlating with the amount of complement-dependent enhancing antibodies and inversely correlating with the CD4+ cell count. 45 Since both types of antibodies exhibit similar increase in time during the progression of HIV disease it is possible that the observed correlation can be considered as a simple coincidence. However, since a high degree of sequence homology between the HIV-1 envelope and immunoglobulins zl exists it is possible that at least a part of anti-Fab autoantibodies can enhance HIV-1 infection.
Antibodies against 60kD heat-shock proteins
There are no data currently present on anti-heat-shock protein (hsp) antibodies in retroviral infections in spite of the pathogenic role of anti-hsp60 and anti-hsp70 antibodies in several human infections. 7 It was reported that physically purified and disrupted HIV and SIV viruses contain an bsp60-related protein. 3 Since healthy blood donors might possess cross-reactive autoantibodies against different proteins belonging to the chaperonin 60 family of stress proteins (most probably elicited by bacterial infections) we found it interesting to test on the one handwhether these antibodies have any influence on the susceptibility to HIV-1 infection. On the other hand, HIV-l infection is characterized by very rapid dynamics: about 1 to 10 billion viral particles are produced and cleared each day depending on the stage of the diseaseY We investigated therefore if the continuous antigenic stimuli by HIV-associated hsp60-1ike molecule is able to induce humoral immune response to hsp60. According to our results 29 the level and distribution of anti-hsp65 antibodies were found to be very similar in the sera of HIVpatients (23.38+17.36 U/ml; 19.3-27.46 U/ml, mean_+SD; CI, n=73) compared to the control individuals (24+25.69 U/ml; 20.57-27.44 U/ml, mean+SD; CI, n=217). The amounts and distribution of anti-human hsp60 antibodies were also found to be very similar. A gradual decrease in time was observed in the level of anti-hsp65 and anti-hsp60 antibodies, whereas no significant decrease of total serum IgG could be observed in the follow-up period. The decrease of anti-hsp65/60 antibodies coincided with the decrease in the CD4+ cell counts in the 14 HIV-1 infected patients studied longitudinally. Our data indicates that antibodies against different 60kD heat-shock proteins are present in HIV-1 infected patients.
The presence of the anti-hsp60 autoantibodies does not affect susceptibility to HIV-1 infection since the distribution of this type of autoantibodies is very similar in seronegative and HIV seropositive patients. There is a decline in the level of this type of autoantibodies in HIV-1 infection. The disappearance of anti-hsp60/65 antibodies coincides with the immunological progression (decline of CD4+ cell count).
Antibodies reacting with the Clq subcomponent of the first complement component (ClqAb)
HIV-1 transmembrane glycoprotein gp41 binds the first component of the classical complement pathway, ~ subsequent activation of the macromolecular C1 by the HIV-I particles may result in the development of Clqcoated virions that may facilitate the formation of ClqAb. This possibility was strongly supported by the observations of Stoiber et al. :~ on the functional and structural similarities of Clq and gpl20. The two proteins were found to compete for the same binding sites on gp41. 39 In spite of these indirect evidences for the possibility of development of C lqAb in HIV-infection, to the best of our knowledge no systematic titration of ClqAb in the sera of HIV-infected subjects has been performed so far, According to our recent study (Proh~.szka et al., manuscript in preparation) highly significant increases in the frequency ,and amounts of C lqAb were found in the H1V-infected subjects as compared to the HIV-seronegatire controls. The titer of ClqAb significantly decreased during the follow-up period.
Correlation between autoantibodies, enhancing antibodies and disease parameters
The design of our study allowed us to calculate correlations between the parameters tested in the same cohort of HIV-1 infected patients. As shown in Table 4 based on our recent study (Proh~szka et al., manuscript in preparation), significant positive correlation was found between anti-hsp60 and C lq Ab. CDEA inversely correlated to the levels of these autoantibodies, while (in accordance with our previous work 4~) there was a positive correlation between CDEA and anti-Fab antibodies with the exception of IgG anti-Fab. Different types of anti-Fab antibodies also significntly correlated to each other. Experiments aiming to clarify the mechanism and clinical significance of these correlations are in progress in our laboratories.
